Jiang Xinguo, Tian Wen, Kim Dongeon, McQuiston Alexander S, Vinh Ryan, Rockson Stanley G, Semenza Gregg L, Nicolls Mark R
VA Palo Alto Health Care System, Palo Alto, CA, United States.
Stanford University School of Medicine, Stanford, CA, United States.
Front Pharmacol. 2022 Mar 28;13:851057. doi: 10.3389/fphar.2022.851057. eCollection 2022.
Lymphedema is a chronic inflammatory disorder characterized by edema, fat deposition, and fibrotic tissue remodeling. Despite significant advances in lymphatic biology research, our knowledge of lymphedema pathology is incomplete. Currently, there is no approved pharmacological therapy for this debilitating disease. Hypoxia is a recognized feature of inflammation, obesity, and fibrosis. Understanding hypoxia-regulated pathways in lymphedema may provide new insights into the pathobiology of this chronic disorder and help develop new medicinal treatments.
淋巴水肿是一种慢性炎症性疾病,其特征为水肿、脂肪沉积和纤维化组织重塑。尽管淋巴生物学研究取得了重大进展,但我们对淋巴水肿病理学的了解仍不完整。目前,尚无针对这种使人衰弱的疾病的获批药物疗法。缺氧是炎症、肥胖和纤维化的一个公认特征。了解淋巴水肿中缺氧调节的通路可能为这种慢性疾病的病理生物学提供新见解,并有助于开发新的药物治疗方法。